Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-09
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Hi, everyone. Thank you for joining us on the first day of the Guggenheim Healthcare Innovation Conference. My name is Rosie Lau. I'm a member of the biotech research team here at Guggenheim Securities. With me, I have a team from Crescent Bio. I'm Joshua Brum, CEO, LEM, CMO, and Jonathan McNeil, President and Chief Operating Officer. Welcome. Great to have you here today. Thank you. So just to start off, maybe for those less familiar with the story, could you start with a quick overview of Crescent Bio and where the company is today across the pipeline?
I'd be happy to, and thanks again for inviting us today. We will be making some forward-looking statements, so please refer to our SEC filings for those matters. Look, I think it's been a really exciting and, I guess, you know, very, very fast period of time since Jonathan and I joined Crescent in March of 2025. We did so with the premise that our belief in the next generation IO backbone bispecific class was going to be successful. At the time, there's still a lot of questions around that. I think that's been substantially answered since we joined, and so we thought that was a really important pillar of our business is being to have one of the only next-gen I.O. backbone therapies for oncology, but we also thought and had a strategy and view that cognizant therapy is where the puck was moving, and so in addition to the I.O. backbone and our CR001 asset, We built a sleeve of ADC assets as well, and so we're constantly thinking about combination strategies, thinking about what we can combine with our bispecific, whether that's additional ADCs through a massive partnership we have with Colune in China, or other modalities or ADCs that we're thinking about combining with our O-1 assets. So we really do believe in our strategy on combinations will win. We've since started in March 25, as I mentioned, now we have three programs in the clinic. Our bispecific CR001 went in earlier this year. Our first wholly owned ADC, our PD-L1 topo ADC, CR002, started dosing patients this quarter. And then our CR003 asset, which is our IV6 topo ADC, which we licensed from Colun, went into clinical studies and phase 1, 2 studies in China earlier this year through our partner, Colun. All of that means that starting in Q1, 2027, we're going to have a plethora of data coming, whether it's the monotherapy first-line lung with CR001. One, it's the combination standard care chemo combos with CR001 coming in the middle of next year, or the SAC TMT01 combo data coming from Kulun middle of next year as well through the ADC portfolio. And so we're really primed for a big 2027 and excited about the progress we've made to date.
Great. Thank you for that overview. Just maybe to follow up on the strategy here, you know, you framed it as the next IO backbone, and you kind of highlighted it. Two different paths that you're taking with the standard-of-care chemo combinations as well as ADC. I guess, can you elaborate? How do you prioritize between these two strategies?
Yeah, Jonathan, you want to take this one?
Yeah, so our vision has always been to have a matrix portfolio, which is across the 40 to 50-plus solid tumor indications we could address with our pipeline, what are the best assets that we could use to make the biggest difference for patients? And the focus there is on an indication-by-indication basis. For select indications, it'll make sense to combine next-gen I.O. with standard-of-care chemo combos. For others, there's an opportunity to combine with ADC portfolio. And again, this is perhaps best exemplified by a Colune relationship, Colune being a leading developer of SAC TMT and multiple other ADCs. And what that allows us to do is explore both ADCs as monotherapy and in combination with OO1 in a very capital efficient way. And it includes both our wholly owned ADC pipeline, but also the entire pipeline that Colune has as well. And we get access to that data. But I'd expand your question to say that it's even beyond those two modalities, which is if 001 proves to be the next-gen IO backbone that we've designed it to be, then we also have the opportunity to combine with small molecules inhibitors, be it KRAS or otherwise, and other elements here. And it's an indication-by-indication basis, and it really speaks to the breadth of our opportunity in this $100 billion-plus market. And so our strategy is, how do we lead and select large indications? And this will be driven by both our own data, the competitive landscape, and, of course, The opportunity we have to partner with others, and the nice thing about this is that the data we're generating in 2027 across O1 monotherapy, O1 standard care chemo combos, O1 ADC combos, and ADC monotherapy will only increase the interest we have that's already substantial today around partnering O1 to develop the best combination therapies possible for patients.
Yeah, maybe I'll just add to that. Just I think people need to really think about the opportunity that we truly have and understand it. So as we talked about our priorities, and it's a great question, where do we go? How do we how do we think about standard chemo combos or ADC combos? You know, we have a really unique opportunity. I think what Ellie and the team have done on execution, on generating and our focus on generating meaningful clinical data is going to really drive drive the car here. And it's going to put us in a position, as we've mentioned in a press release, we put out A couple weeks ago, that by middle of next year, we're going to have over 2,000 patients dosed. We're going to generate a robust data set across our portfolio. And that's going to allow us to start phase three studies in early 28. And what's unique about this opportunity for us is because you're replacing the first-gen backbone IO label of the coutures of the world, the first-gen PD-1s, that's a $50 billion market opportunity. Now it's expanded because we're We're seeing the opportunity that the VEGF component brings to the bispecific. You see activity now in indications like CRC. And so as Jonathan mentioned, it's a $100 billion market opportunity. We're going to have our first opportunity to start multiple phase three studies. And we think about a phase three study is about revenue. So, you know, in our foundational revenue of the first-gen strategy of our phase three studies, every phase three study that we start, whether it's a standard care chemo combo, which is likely where we will start across these indications, We're replacing the labels of the first-gen PD-1s. We think for us that's a $2 to $10 billion market opportunity. And if you think about, you know, industry leaders in the top 10 oncology franchises, you think about a company like Gilead. Gilead does $3 billion of revenue. It's a top 10 oncology franchise. And our first foundational set of revenue opportunity from our phase three studies, we can easily see a path to $2 to $10 billion of opportunity. And then you get to the dream of winning in combos, and then combining 001 with ADCs or other modalities, and that comes behind our first set of phase three studies. That's where you have the opportunity to be best in class and actually win best in class in indications like Lung or CRC or other massive indications. And so there, the revenue is almost infinite, right? And so if you think about what the value we have with our strategy, not just owning the bispecific and O01, but then thinking about all the ways we can combine O01 as the next-gen backbone in oncology, it truly is a massive opportunity from revenue generation and really changing treatment paradigm for patients living with cancer. No, that's great.
And Jonathan, you mentioned the competitive landscape earlier. Obviously, it's been a very eventful few months for the PD-1 VEGF class. You know, there was some data at ESMO. We had the Harmony 3 Squamous interim miss earlier this year. Perhaps just at a high level to start, maybe we can dive into the moving pieces in a bit. What has been the most encouraging thing you've seen to date?
Sure. Ellie, you want to take that one? Yeah.
Yeah. I mean, I think it's a really great question that when IVANESMEP data started to emerge, there were a lot of questions on PFS benefit versus OS benefit. Is it going to translate? And what about the safety and tolerability of VEGF? And is it going to be only in lung? Or can we see that benefit in other indications? We're very happy to see that emerging data has been answering all those questions one by one. So with the HARMONY-2 and HARMONY-6 studies, IVENESMEP demonstrated a superior PFS as well as a survival benefit in first-line non-small-cell lung cancer patients showing superiority compared to PD-1 inhibitors, which thus far no other compound has done in randomized phase 3 setting. And then, biliary trachyter, Harmony GI1 study, was a really great example, to Josh's point. This is not just a non-sumosal lung cancer play. There are multiple other indications where PD-1 VEGF can replace existing PD-1 inhibitors and then provide a superior outcome. So, so far, what we are seeing is really supporting our initial hypothesis of building this company with the next generation IO backbone, as well as how potentially we can find the best synergistic combination partners, which we have seen with our partner, Columne-7-DMT, with Optitrope Long 05 and Long 06 study as well. So we are very encouraged to see the emerging data and supporting our mission in this oncology biotech as finding the best possible combination options for the patients.
I would say, and, you know, look at the competitive landscape, all the data that's out there, I would encourage people to go back and look at the first movie, right, which is the PD-1, you know, development, and you think about, you know, Optivo, Keytruda, you know, Ellie had a very big success with Tesaro and Jen Perley being the seventh PD-1 approved, and people have to remember that, you know, many of those phase three studies failed, and here we are with the next-gen IO backbone, the first four studies read out in a And I think we think that'll be a positive outcome, at least on the PFS side, and most likely OS as well. But... You can see how in that first iteration of the PD-1s, you know, those who started first didn't finish first. Execution is going to matter. Our bet's on clinical strategy. And also, I think, you know, I want to point out the importance of safety. You're seeing a lot of the, you know, next-gen PD-1 bispecifics showing similar efficacy, but I would also encourage people to focus on the safety profile. Because if you want to be a true backbone therapy, and you want to combine, and you want to have best-in-class therapies, safety is going to be just as important as efficacy here.
Great. Maybe just on Harmony 3, you mentioned that you think the PFS and O's could be positive, which I think those data are reading out later this year. I guess, what would you look at beyond the headline HR, and I guess, how could those outcomes and maybe some of these regulatory debates kind of shape your own strategy for 001?
Yes, I mean, this is with the HARMONY study, PDUFA date coming up, and then HARMONY 3, final PFS and interim OS data readout coming up. I think this is really an exciting moment for the field. From our perspective, based on HARMONY 6 data, showing robust PFS benefit and OS benefit in squamous non-small cell lung cancer patients, And then with multiple trials showing consistent survival benefit between Chinese patients and the global patients, we think that likelihood of HARMONY-3 study showing clinically meaningful PFS benefit is high. And then, of course, OS might take a little longer for us to read out. And so we are very excited to see that data. And from our perspective, we are in a really great position to learn from these trial outcomes and focusing on our execution. So from our perspective, we have this unique advantage of we are part of the first many companies that are trying to develop PD-1 VEGF in the global stage. And Ascend study, which is our global phase one to study, we are generating this data in the United States, Europe, and South Korea. But also we have data coming from our partner, Colun. With these two approaches, we don't have to transition from Chinese data to the global data and gaining experience working with the FDA as well as EMA. And so, we are in a great place, continuing on with our execution, but we will learn from the data that is emerging to make sure that we have all the efficiency as possible.
And I would just maybe add that, you know, our team has done a phenomenal job of executing our way into the leaders of this next-gen IO backbone therapy coming. I think that, you know, as I mentioned, we've seen four positive studies here right out of the gates. I think that pharma has largely shifted their view from kind of sitting on the fence and maybe waiting ahead of the ASCO Harmony 6 readout to now everyone trying to figure out, how do I get a backbone therapy play here for my pipeline, my ADCs, and how do I play here? And so while I do think the Harmony 3 readout is important, I do think it's a specific issue for Summit. It is not a class issue, right? And so, as I mentioned, you know, the Activa, Catruda, Jim Perley, all the other PD ones that have jockeyed for position prior to in the first part of this movie, we'll see that unlikely again. And we're now situated through our execution in a very strong position. And that's why I said things like manufacturing, are you ready? Commercial, are you ready? You know, thinking about safety, how important that's going to be. There's going to be differentiators here that allow people to get a piece of this market, and it's so big, and the opportunity is so big for patients that I just think that there's a lot of opportunity for multiple companies to win, but I'm proud of the execution that our company's had and putting ourselves in a leadership position here in a very short period of time. It's such a big market opportunity. Great.
Thank you. And perhaps that's a good segue into my next question and talking about your own pipeline. You have a very busy year coming up, as you alluded to earlier. I believe the ASCEND dose escalation has completed. I guess what should we expect from the first quarter data from the monotherapy dataset next year? Yeah.
Well, you want to kind of walk through your expectations for the Q1 data and then kind of the rest of the year?
Yeah, sure. So let me first remind you how the study is designed. So ASCEND is phase 1, 2 study of CR001, our PD-1 VEGF by specific. We have eight different tumor types in three therapeutic areas, lung, GI, and GYNC. So we have dose escalation followed by monotherapy backfill cohorts at those levels that we have tested. And so Q1 2027 data release will focus on these three things. Safety tolerability of all patients who have been tested and then dosed. So we have already stated that we have more than 125 patients dosed, so it will be a very comprehensive data set. And then we have PK as well as pharmacodynamics data to support that this compound was built and then match the clinical profile of Ibanez map. And then, last but not least, we will provide anti-tumor activity data from first-line non-small-cell lung cancer patients because that probably is the indication we can clearly demonstrate and compare anti-tumor activity of CR001 to ibanesimab. And in the middle of next year, followed by that data release, we will also provide comprehensive safety, tolerability, and efficacy data from our expansion cohorts. And in that expansion cohorts, we are combining CR001 with various chemotherapy backbones. We will have data from first-line cohorts of non-small cell lung, biliary, endometrial, and colorectal, as some of many. And then we'll also have our data from Colun showing the synergistic combination of a SEC-TMT plus CR001. So we have a lot of data set coming from Ascend study as well as with our partner of Colun, and this data set will clearly demonstrate how CR001 is really the next generation IO backbone, and then also charting our path for starting phase three study, our first phase three study in early 2028 as well.
And I'd add, and we can talk more about this, but we also have additional data coming around our ADC portfolio. So we have... In the first half, in the first quarter, we're going to have data, monotherapy data, with our partner Colune from the Integrin Beta 6 Topo ADC that we've been licensed from Colune. We have rights to it everywhere outside of Greater China. That data, monotherapy set will be coming in the first quarter, 27, and then in the second half of the year, we'll have data from CRO2, which is our internally developed PDL1 Topo ADC monotherapy data. So, both of those data sets will be coming as well, and that speaks to the importance of our strategy, both the CRO1 being next-gen IO backbone, all the data Ellie just articulated, our wholly owned ADC portfolio, and the opportunity to combine those. I'd also add that, and part of our Colune structure, they have the opportunity to combine O1 with any ADC in their portfolio. So, the first three studies that they've disclosed are focused on SAC TMT, but if you look at Colune's publicly disclosed portfolio, they also have ADCs targeting B7H3. They have Claudin, they have Nectin ADC. So what I'd say is stay tuned for the opportunity for more data to come, combining O01 with the rest of the Kaloon's pipeline. And I bring that up because if you think about the preponderance of data we could have over the course of 2027, it really does speak to that synergistic combination strategy that Crescent was founded to execute upon.
Yeah, I would just maybe say that, as Jonathan mentioned, stay tuned on what Colum's going to do. I think they're going to lay a roadmap out for what you've seen other companies and big pharma try to do. So you've seen the Treveldi-Gilead-BMS collaboration for just TNBC, right? So obviously, thinking about Gilead, trying to figure out how they're going to use next-gen IO backbone with their portfolio. You saw AC's investment in Summit, right? Well, Kulun was pretty smart, so they just got their own backbone through our trade with O3 and O1. We got our ADC for IB6 that we're super excited about. But you'll see likely Kulun just take that and run that across their entire portfolio of ADCs. And that's kind of a roadmap for what pharma is going to want to do with the backbone therapy. And so that's why I continue to say that it's unique for us to have that opportunity to own O1 and have our own combinations across our pipeline of strategy.
Great. Maybe we can just circle back to the monotherapy dataset that's coming up in first quarter. I guess how should we think about the benchmarks there?
So, the clinical data that we are presenting in Q1-2027 is focusing on monotherapy CR001. So, safety tolerability and PK and pharmacodynamics data, our benchmark is comparability to that of Ivernosmet phase 1 study in previously treated solid tumor patients. And in terms of anti-tumor activity of first-line non-small cell lung cancer patients, we are looking at around 50% of ORR, which is what we saw from Ibanez metmonotherapy in Harmony 2.
Great. And Ellie, you also mentioned, you know, there's several different chemo combo cohorts in expansion. I believe there's seven, if I'm not mistaken. And you said that indication selection will be, you know, data-driven, I guess. As those chemo combo data readout mid-next year, what will we weigh most and heavily in deciding kind of which ones to take into registration?
Yeah, of course, our data will always drive our decisions and more how we prioritize. But as Jonathan mentioned, you know, thinking about how broad we can go in this first wave of foundational revenue in our phase three study starts, how many phase threes can we start? How do we think about partnering potentially to go broader? But also the competitive landscape will continue to be part of our thoughts there as well.
Great. And maybe circling back to your in-house ADC portfolio, like Jonathan mentioned earlier in our last couple of minutes, the Apollo study was guided to start this quarter. I guess, what are the gating items prior to initiation of that trial? And I guess, how quickly can dose escalation get you to an RB2D ahead of the data at the end of next year?
There's no gating items, so stay tuned. Yeah, so that's... You've seen our execution across other programs, so we're very confident in how we're going to enroll that trial in the U.S. and globally, and then generate the data in the second half of next year. And just a reminder that RO2, it's a PD-L1 topo ADC, which we're very excited about. It developed internally, and we think it's differentiated from other assets you see in the space, such as Pfizer, which has a PD-L1 MME ADC. And then, yeah, so we're very excited about that initiating and look forward to sharing more data in the second half of next year.
Great. Let me just wrap up. You know, you kind of mentioned the Calhoun partnership, and there's a pretty unique structure to that partnership here. I guess, as you think about the landscape and the assets that you have today, I guess, any additional thinking around ongoing discussions for partnering out?
Yeah, I mean, look, I would say that if we're very excited with our partnership with Colune, it is a unique structure where they have rights to O1 in China. We have rights, of course, for the rest of the world, and then we have the inverse rights for the Integrate Beta 6 ADC. The Colune partnership is an important partnership for us to generate data, particularly around ADC combinations data quickly. That being said, if O01 does become the next-gen IO backbone that we believe it can be, there's clearly an opportunity for additional partnerships globally, either across select indications or more broad partnerships. So stay tuned. It's a key element of our strategy, but we are focused on developing our wholly owned portfolio and maintaining meaningful rights to our portfolio.
Yeah, I say this every time, but it's important to partner partners and other partners together. We love collaborating. We are open for business. We have the backbone with a one asset to do that and do some very unique things and creative things. I think the Kloon partnership for a company our size when we did it was quite unique. And so I think people start to realize, you know, within, you know, two years of taking these three assets from preclinical stage to clinical stage and generating over 2,000 patients worth of data, You can show the power of a truly good collaboration, and so we're open for business, we're looking to collaborate, and we're excited about the pipeline we have to execute on it.
Great, and with that, I think we're up on time. Thank you, Joshua, Ellie, and Jonathan for joining us today.
0:00 to 24:05 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Hi, everyone. Thank you for joining us on the first day of the Guggenheim Healthcare Innovation Conference. My name is Rosie Lau. I'm a member of the biotech research team here at Guggenheim Securities. With me, I have a team from Crescent Bio. I'm Joshua Brum, CEO, LEM, CMO, and Jonathan McNeil, President and Chief…
Joshua Brumm: I'd be happy to, and thanks again for inviting us today. We will be making some forward-looking statements, so please refer to our SEC filings for those matters. Look, I think it's been a really exciting and, I guess, you know, very, very fast period of time…
Also speaking: Jonathan McNeill, Ellie Im